Haemodialysis Outcomes & Patient Empowerment Study 03 (HOPE-03)

May 18, 2023 updated by: Royal College of Surgeons, Ireland

Pilot-scale, Single-arm, Observational Study to Assess the Utility of a Machine Learning Algorithm in Assessing Fluid Status in Haemodialysis Patients

This is a prospective, single-arm observational study that aims to assess the validity and reproducibility of an algorithm for assessing fluid status in a cohort of dialysis patients.

The study will externally validate an existing algorithm for dry weight prediction in real-time in a cohort of dialysis patients.

Study Overview

Status

Completed

Detailed Description

Volume Overload is a contributing factor to the high rates of cardiovascular and all-cause mortality demonstrated in haemodialysis patients. At present, no method exists that can consistently refine volume status and provide patients with feedback to allow adjustments to their fluid intake. Current standards used to assess volume are either poorly predictive of fluid status, cumbersome to use, or lack an adequate patient interface.

An automated, accurate and periodic assessment of dry weight would be clinically useful, low-cost, and rapidly scalable. Machine learning methods have been widely studied in nephrology. Large amounts of precise haemodialysis data, collected and stored electronically at regular intervals, have the potential to be leveraged in the prediction of patients' extracellular volume or ideal fluid status.

A number of proof-of-concept machine-learning models for the prediction of dry weight in haemodialysis data have been created using retrospective data. This study will evaluate the usability of the machine learning models in managing fluid volume in haemodialysis patients while also assessing their validity and reproducibility against validated measurements; in this instance the Body Composition Monitor (BCM) by Fresenius.

As the machine learning model for assessing fluid status was trained and tested on retrospective data, there is sufficient justification for testing the model's performance, acceptability and usability in a controlled, observational prospective study.

This will be an 8-week trial with a 2-week run-in period conducted in a single centre in Beaumont, Dublin, Ireland. Bioimpedance measurements using the Fresenius BCM will be performed every 2 weeks. Haemodialysis data will be processed continuously throughout the trial. The algorithm will use haemodialysis data to predict the BCM output. The algorithm prediction will be compared to the BCM prediction to assess its usability.

Study Type

Observational

Enrollment (Actual)

24

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Sandys
  • Phone Number: +353 1 402 2100
  • Email: info@rcsi.ie

Study Locations

    • Leinster
      • Dublin, Leinster, Ireland, 9
        • Beaumont Hospital
      • Dublin, Leinster, Ireland, D09V2N0
        • Beaumont Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Patients requiring maintenance haemodialysis in an ambulatory care setting.

Description

Inclusion Criteria:

  • Receiving maintenance haemodialysis in an ambulatory care setting
  • Aged at least 18 years
  • Demonstrates understanding of the study requirements.
  • Willing to give written informed consent.

Exclusion Criteria:

  • Conditions precluding accurate use of bioimpedance (e.g. limb amputations,severe malnourishment, pregnancy, cardiac resynchronisation devices, pacemakers).
  • Significant confusion or any concomitant medical condition, which would limit the ability of the patient to record symptoms or other parameters.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Haemodialysis patients
Haemodialysis patients attending haemodialysis in an outpatient setting in Beaumont Hospital, Ireland.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The primary objective is to determine the validity of the machine learning model in estimating bioimpedance-determined dry weight in haemodialysis patients.
Time Frame: 8 weeks
Dry weight (kg) estimated by the machine learning estimation model will be compared with the bioimpedance normohydration weight in kg.
8 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Acceptability
Time Frame: 8 weeks

The acceptability of the machine learning model's outputs from a clinical healthcare perspective will be assessed.

  • The patient's clinical fluid status will be assessed via a survey administered to haemodialysis nursing staff every 2 weeks pre-dialysis. The survey will ask the haemodialysis nursing staff to define a patient's fluid overload in kg.
  • The mean difference between fluid overload in kg as defined by healthcare staff and fluid overload in kg as defined by the algorithmic output will be assessed.
8 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Collaborators

Investigators

  • Principal Investigator: O'Seaghdha, Royal College of Surgeons in Ireland

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 14, 2023

Primary Completion (Actual)

April 27, 2023

Study Completion (Actual)

April 27, 2023

Study Registration Dates

First Submitted

November 30, 2022

First Submitted That Met QC Criteria

February 9, 2023

First Posted (Actual)

February 21, 2023

Study Record Updates

Last Update Posted (Actual)

May 19, 2023

Last Update Submitted That Met QC Criteria

May 18, 2023

Last Verified

November 1, 2022

More Information

Terms related to this study

Other Study ID Numbers

  • 21/82

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Dialysis

3
Subscribe